Download PDF
Thromb Haemost 1981; 46(02): 504-506
DOI: 10.1055/s-0038-1653397
Original Article
Schattauer GmbH Stuttgart

Antithrombin III, the Major Modulator of Intravascular Coagulation, Is Synthesized by Human Endothelial Cells

T K Chan
The Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
,
Vivian Chan
The Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
› Author Affiliations
Further Information

Publication History

Received 20 March 1981

Accepted 04 May 1981

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Human endothelial cells in culture is shown to synthesize antithrombin III (At-III). The endothelial cell At-III(EC-At-III) consists of a small fraction similar to plasma At-III and a larger fraction with decreased heparin-binding as tested by crossed immunoelectrophoresis. However, both the anti-Xa and thrombin-neutralizing activities of the EC-At-III were rapid and active even in the absence of added heparin. It is concluded that the major portion was probably bound to endogenous heparin-like substance, thus accounting for its decreased exogenous heparin binding. The presence of At-III and other antithrombotic factors in the vascular endothelium offer protection against thrombosis and possibly atherosclerosis.

Keywords

Human endothelial cells - Antithrombin III synthesis - Anti-Xa and thrombin neutralizing activities
 

  • References

  • 1 Fell C, Ivanovic N, Johnson SA, Seegers WH. Differentiation of plasma antithrombin activities. Proc Soc Exp Biol Med 1954; 85: 199-202
    CrossrefPubMedGoogle Scholar
  • 2 Lane JL, Biggs R. The natural inhibitors of coagulation – antithrombin III, heparin cofactor and antifactor Xa. In Recent Advances in Blood Coagulation Number 2. ed. Poller L. p 121-139 1977. Churchill Livingston:
    Google Scholar
  • 3 Seegers WH, Warner ED, Brinkhous KM, Smith HP. Heparin and antithrombic activity of plasma. Science 1942; 96: 300-301
    CrossrefPubMedGoogle Scholar
  • 4 Monkhouse FC, France ES, Seegers WH. Studies in antithrombin and heparin cofactor activities of fraction absorbed from plasma by aluminium hydroxide. Circ Res 1955; 3: 397-402
    CrossrefPubMedGoogle Scholar
  • 5 Abildgaard U. Purification of two progressive antithrombins of human plasma. Scand J Clin Lab Invest 1967; 19: 190-195
    CrossrefPubMedGoogle Scholar
  • 6 Seegers WH, Marciniak E. Inhibition of autoprothrombin C activity with plasma. Nature 1962; 193: 1188-1190
    PubMedGoogle Scholar
  • 7 Biggs R, Denson KW, Akman N, Borrett R, Hadden M. Antithrombin III, antifactor Xa and heparin. Brit J Haemat 1970; 19: 283-305
    CrossrefPubMedGoogle Scholar
  • 8 Yin ET, Wessler S, Stoll PJ. Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. J Biol Chem 1971; 246: 3712-3719
    PubMedGoogle Scholar
  • 9 Rosenberg RD. Chemistry of the haemostatic mechanism and its relationship to the action of heparin. Fed Proc 1977; 36: 10-18
    PubMedGoogle Scholar
  • 10 Chan TK, Chan V. The effect of venous occlusion on antithrombin III, plasminogen activator and fibrinogen degradation product (fragment E) levels. Thromb Res 1979; 14: 525-534
    CrossrefPubMedGoogle Scholar
  • 11 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
    PubMedGoogle Scholar
  • 12 Marciniak E, Farley CH, DeSimone PA. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-231
    PubMedGoogle Scholar
  • 13 Filip DJ, Eckstein JD, Veltkamp JJ. Hereditary antithrombin III deficiency and thromboembolic disease. Am J Haemat 1976; 2: 343-349
    PubMedGoogle Scholar
  • 14 Abildgaard U, Fagerhol MK, Egeberg O. Comparison of progressive antithrombin activity and the concentrations of three thrombin inhibitors in human plasma. Scand J Clin Lab Invest 1970; 26: 349-354
    CrossrefPubMedGoogle Scholar
  • 15 Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65: 607-613
    CrossrefPubMedGoogle Scholar
  • 16 Losito R, Barlow G, Lemieux E. 3H-Heparin and antithrombin III in the isolated liver perfusion. Thromb Res 1977; 10: 83-93
    CrossrefPubMedGoogle Scholar
  • 17 Koj A, Regoeczi E, Toews CJ, Leveille R, Gauldie J. Synthesis of antithrombin III and alpha-1-antitrypsin by the perfused rat liver. Biochim Biophys Acta 1978; 539: 496-504
    CrossrefPubMedGoogle Scholar
  • 18 Owens MR, Miller LL. Net biosynthesis of antithrombin III by the isolated rat liver perfused for 12–24 hrs. Compared with rat fibrinogen and α-2 (Acute phase) globulin, antithrombin III is not an acute phase protein Biochim Biophys Acta 1980; 627: 30-39
    CrossrefPubMedGoogle Scholar
  • 19 Lee AK Y, Chan V, Chan TK. The identification and localization of antithrombin III in human tissues. Thromb Res 1979; 14: 209-217
    CrossrefPubMedGoogle Scholar
  • 20 Chan V, Chan TK. Antithrombin III in fresh and cultured human endothelial cell: a natural anticoagulant from the vascular endothelium. Thromb Res 1979; 15: 209-213
    CrossrefPubMedGoogle Scholar
  • 21 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci 1974; 71: 1906-1909
    CrossrefPubMedGoogle Scholar
  • 22 Chan V, Chan TK. Heparin-antithrombin III binding, in vitro and in vivo studies. Haemostasis 1979; 8: 373-389
    PubMedGoogle Scholar
  • 23 Chan V, Chan TK, Wong V, Tso SC, Todd D. The determination of antithrombin III by radioimmunoassay and its clinical application. Brit J Haemat 1979; 41: 563-572
    CrossrefPubMedGoogle Scholar
  • 24 Gitel SN, Wessler S. Plasma Antithrombin III: a quantitative assay of biological activity. Thromb Res 1975; 7: 5-16
    CrossrefPubMedGoogle Scholar
  • 25 Andersson LO, Engman L, Henningsson E. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III-thrombin complex J Immun Methods 1977; 14: 271-281
    CrossrefPubMedGoogle Scholar
  • 26 Buonassisi V. Sulfated mucopolysaccharide synthesis and secretion in endothelial cell cultures. Exp Cell Res 1973; 76: 363-368
    CrossrefPubMedGoogle Scholar
  • 27 Thomas DP, Barrowcliffe TW, Johnson EA, Stocks J, Dawes J, Pepper DS. A heparin analogue that releases endogenous heparan sulphate. Thromb Haemostas 1979; 42: 418 (Abstr.)
    PubMedGoogle Scholar
  • 28 Tran TH, Bondeli C, Marbet GA, Duckert F. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa. Thromb Haemostas 1980; 44: 92-95
    PubMedGoogle Scholar
  • 29 McDonald RI, Shepro D, Rosenthal M, Booyse FM. Properties of cultured endothelial cells. Ser Haemat 1973; 4: 469-478
    PubMedGoogle Scholar
  • 30 Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci 1977; 74: 3922-3926
    CrossrefPubMedGoogle Scholar
  • 31 Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1977; 01: 18-20
    PubMedGoogle Scholar
  • 32 Ross R, Glomset JA. The pathogenesis of atherosclerosis. New Eng J Med 1976; 295: 369-377
    CrossrefPubMedGoogle Scholar
  • 33 Lerner RG, Cheong LC, Nelson JC. Thrombin-induced endothelial cell retraction. Thromb Haemostas 1979; 42: 244 (Abstr.)
    PubMedGoogle Scholar
  • 34 Chen SC, Barmatowski S, Barnhart MI. Impact of thrombin on platelet-vessel wall interactions. Thromb Haemostas 1979; 42: 233 (Abstr.)
    PubMedGoogle Scholar